Tiba Biotech LLC, a for-profit limited liability company, was awarded a $749,999.01 firm-fixed-price contract (Contract ID: 75A50124C00014) by the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, for research and development of a respiratory virus treatment using lung-targeted small interfering RNA (siRNA) delivery. The contract, which does not have a set-aside designation, is scheduled for completion by October 31, 2025. Tiba Biotech specializes in developing innovative RNA vaccine technologies, including rapid-response platforms and delivery approaches for various infectious diseases. The company has also served as a subcontractor on federal grants, providing RNA vaccines to support studies on influenza immunity and protection.
Generated 11/30/24, 9:28 AM